<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27066572</article-id>
<article-id pub-id-type="pmc">4811385</article-id>
<article-id pub-id-type="publisher-id">NG2015000638</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000035</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>60</subject>
<subject>94</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Novel <italic>GABRG2</italic> mutations cause familial febrile seizures</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Boillot</surname>
<given-names>Morgane</given-names>
</name>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Ligue Fran?aise contre l'Epilepsie</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morin-Brureau</surname>
<given-names>MÃ©lanie</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Picard</surname>
<given-names>Fabienne</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>a grant from the Swiss National Foundation No. 320030-127608</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weckhuysen</surname>
<given-names>Sarah</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>French program ?Investissements d?avenir? (ANR-10-IAIHU-06)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lambrecq</surname>
<given-names>Virginie</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>(1) French program</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Minetti</surname>
<given-names>Carlo</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Striano</surname>
<given-names>Pasquale</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zara</surname>
<given-names>Federico</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iacomino</surname>
<given-names>Michele</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ishida</surname>
<given-names>Saeko</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) Japan Society for Promotion of Science (JSPS)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>An-Gourfinkel</surname>
<given-names>Isabelle</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Daniau</surname>
<given-names>Mailys</given-names>
</name>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hardies</surname>
<given-names>Katia</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Katia Hardies was a PhD fellow of the Institute for Science and Technology (IWT)-Flanders.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baulac</surname>
<given-names>Michel</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>UCB Eisai GSK SAGE GW Pharma</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>Received travel expenses and/or honoraria for lectures or educational activities funded by industry UCB, Received travel expenses and/or honoraria for lectures or educational activities funded by industry UCB, Eisai GSK isai GSK</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>UCB: review of study protocols Eisai: review of study protocols GSK: review of study protocols</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dulac</surname>
<given-names>Olivier</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leguern</surname>
<given-names>Eric</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) Program ?Investissements d?avenir? ANR-10-IAIHU-0 (2) INSERM (3) Assistance Publique des H?pitaux de Paris</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nabbout</surname>
<given-names>Rima</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Novartis</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>Funding for travel from Shire Speaker honoraria from Novartis, cyberonics, Eisai</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>editorial advisory board member of Epilepsia</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Baulac</surname>
<given-names>StÃ©phanie</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) Program ?Investissements d?avenir? ANR-10-IAIHU-06,(2) Carnot Institute [N? CT010]</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From Sorbonne UniversitÃ©s (M.B., S.I., M.D., S.B., M.M.-B., E.L., S.W., M.B., V.L., I.A.-G.), UPMC Univ Paris 06, UM 75, ICM; INSERM, U1127 (M.B., S.I., M.D., S.B., M.M.-B., E.L., S.W., M.B., V.L., I.A.-G.), ICM; CNRS (M.B., S.I., M.D., S.B., M.M.-B., E.L., S.W., M.B., V.L., I.A.-G.), UMR 7225, ICM; ICM (M.B., S.I., M.D., S.B., M.M.-B., E.L., S.W., M.B., V.L., I.A.-G.), Paris, France; Department of Neurology (F.P.), University Hospitals of Geneva (HUG), Switzerland; Centre de Reference Ãpilepsies Rares, Epilepsy Unit (S.W., M.B., V.L., I.A.-G.), and DÃ©partement de GÃ©nÃ©tique et de CytogÃ©nÃ©tique (E.L.), AP-HP Groupe Hospitalier PitiÃ©-SalpÃªtriÃ¨re, Paris, France; Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova (C.M., P.S.), and Laboratory of Neurogenetics, Department of Neurosciences (F.Z., M.I.), âG. Gasliniâ Institute, Genova, Italy; Neurogenetics Group, VIB-Department of Molecular Genetics (K.H.), and Laboratory of Neurogenetics, Institute Born-Bunge (K.H.), University of Antwerp, Belgium; Centre de Reference Ãpilepsies Rares (O.D., R.N.), Department of Pediatric Neurology, Necker Enfants Malades Hospital, AP-HP, Paris; INSERM (O.D., R.N.), U1129, Necker, Paris, France; and University Paris Descartes (O.D., R.N.), Paris, France.</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Correspondence to Dr. Baulac: <email>stephanie.baulac@upmc.fr</email></corresp>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the article. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000035">Neurology.org/ng</ext-link> for full disclosure forms. The Article Processing Charge was paid by the Institut du Cerveau et de la Moelle (ICM).</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>04</day>
<month>11</month>
<year>2015</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
<volume>1</volume>
<issue>4</issue>
<elocation-id>e35</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>6</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>9</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Â© 2015 American Academy of Neurology</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2015000638.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<sec>
<title>Objective:</title>
<p>To identify the genetic cause in a large family with febrile seizures (FS) and temporal lobe epilepsy (TLE) and subsequently search for additional mutations in a cohort of 107 families with FS, with or without epilepsy.</p>
</sec>
<sec>
<title>Methods:</title>
<p>The cohort consisted of 1 large family with FS and TLE, 64 smaller French families recruited through a national French campaign, and 43 Italian families. Molecular analyses consisted of whole-exome sequencing and mutational screening.</p>
</sec>
<sec>
<title>Results:</title>
<p>Exome sequencing revealed a p.Glu402fs*3 mutation in the Î³2 subunit of the GABA<sub>A</sub> receptor gene (<italic>GABRG2</italic>) in the large family with FS and TLE. Three additional nonsense and frameshift <italic>GABRG2</italic> mutations (p.Arg136*, p.Val462fs*33, and p.Pro59fs*12), 1 missense mutation (p.Met199Val), and 1 exonic deletion were subsequently identified in 5 families of the follow-up cohort.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>We report <italic>GABRG2</italic> mutations in 5.6% (6/108) of families with FS, with or without associated epilepsy. This study provides evidence that <italic>GABRG2</italic> mutations are linked to the FS phenotype, rather than epilepsy, and that loss-of-function of GABA<sub>A</sub> receptor Î³2 subunit is the probable underlying pathogenic mechanism.</p>
</sec>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>Febrile seizures (FS) are the most frequent convulsive event in early infancy, affecting an estimated 2%â5% of children.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> They usually occur between 6 months and 5 years of age in the presence of fever. The prognosis is usually good, although children who have experienced FS have a higher risk of developing epilepsy later in life. Despite a clear genetic component, the genetics of FS is still poorly understood.<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref></sup> Sodium channel and GABA<sub>A</sub> receptor gene mutations have been reported in familial syndromes including FS, such as genetic epilepsy with febrile seizures plus (GEFS+).<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Mutations in 3 ion channel genes collectively account for â¼15% of GEFS+ families: <italic>SCN1B</italic> encoding the voltage-gated sodium channel Î²1 subunit,<sup><xref ref-type="bibr" rid="R5">5</xref></sup>
<italic>SCN1A</italic> encoding the Î±1 subunit of the voltage-gated type I sodium channel,<sup><xref ref-type="bibr" rid="R6">6</xref></sup> and <italic>GABRG2</italic> encoding the Î³2 subunit of the GABA<sub>A</sub> receptor gene.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> Mutations in the <italic>SCN1A</italic> gene are the most frequent cause of GEFS+ to date.<sup><xref ref-type="bibr" rid="R8">8</xref><xref ref-type="bibr" rid="R9">â</xref><xref ref-type="bibr" rid="R10">10</xref></sup> Recently, mutations in <italic>STX1B</italic>, encoding the presynaptic protein syntaxin-1B, were found in 6 families with FS and epilepsy.<sup><xref ref-type="bibr" rid="R11">11</xref></sup> We performed whole-exome sequencing in a large French family with FS and temporal lobe epilepsy (TLE) and identified a pathogenic frameshift mutation in the <italic>GABRG2</italic> gene. We subsequently identified <italic>GABRG2</italic> mutations in 5 of 107 families with FS.</p>
<sec id="s1" sec-type="methods">
<title>METHODS</title>
<sec id="s1-1">
<title>Patients.</title>
<p>The French cohort consisted of 64 families with FS with or without epilepsy. All families were recruited through a national French campaign on genetic studies of familial FS conducted by GÃ©nÃ©thon in 1998â2000 (J.F. Prud'homme, Evry, France). Inclusion criterion for this cohort was the presence of at least 3 family members with FS (with or without associated epilepsy) with a transmission compatible with an autosomal dominant trait. Family members underwent clinical assessment using a detailed questionnaire. Information was also obtained retrospectively from medical records. Probands of all families were negative for <italic>SCN1A</italic> and <italic>SCN1B</italic> point mutations.</p>
<p>The Italian cohort consisted of 43 families with at least 2 first-degree relatives with FS, with or without epilepsy. Patient evaluation included details on clinical features of seizures (semiology, precipitating factors, duration), family and personal history of seizures/epilepsy, and developmental milestones. All the probands were negative for <italic>SCN1A</italic> mutations.</p>
</sec>
<sec id="s1-2">
<title>Standard protocol approvals, registrations, and patient consents.</title>
<p>Written informed consent was obtained from all participants (or the parents of minors). The study was performed with the approval of the Cochin-Port-Royal Hospital Ethics Committee and the G. Gaslini Institute (No. 003771-35).</p>
</sec>
<sec id="s1-3">
<title>Whole-exome sequencing.</title>
<p>Exome sequencing was performed on genomic DNA from peripheral blood of 3 affected members (A/II-1, A/II-4, and A/II-9) of family A. Targeted exome sequencing, library preparation, capture (Human All exon kit V4+UTRs, 70 Mb, Agilent, Interactive Biosoftware, Rouen, France), sequencing, and variant detection and annotation were performed by IntegraGen (Evry, France) using a previously described procedure.<sup><xref ref-type="bibr" rid="R12">12</xref></sup> Variants with low quality (&lt;20) and low VQSLOD (logarithm of odds ratio that a variant is real vs not under the trained gaussian mixture model) (&lt;0) were filtered out. Variants with a read depth &gt;30 and allele read frequency &gt;0.30 were filtered. High-quality variants were further filtered for those predicted to affect the protein-coding sequence (nonsense, missense, frameshift, or essential splice-site) and with a minor allele frequency (&lt;1%) in the exome variant server (<ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>).</p>
</sec>
<sec id="s1-4">
<title>Mutational screening of <italic>GABRG2</italic>.</title>
<p>Follow-up screening of <italic>GABRG2</italic> was done by Sanger sequencing in the 43 probands of the Italian cohort as previously described.<sup><xref ref-type="bibr" rid="R13">13</xref></sup> Screening in the cohort of 64 probands from French families was performed using a targeted epilepsy gene panel (SeqCapEZ custom design, Roche NimbleGen) including <italic>GABRG2</italic>, <italic>GABRA1</italic>, <italic>STX1B</italic>, <italic>PRRT2</italic>, <italic>CHRNA4</italic>, <italic>CHRNA2</italic>, <italic>CHRNB2</italic>, <italic>LGI1</italic>, <italic>DEPDC5</italic>, <italic>KCNT1</italic>, and <italic>EFHC1</italic>. Quality of raw sequencing data was assessed with the FASTQC tool. Reads were trimmed with Trimmomatic. BWA was used to align reads on human genome (hg19). Finally, GATK best practices were applied to call variants. Variants with low quality (&lt;20) were excluded. Variants with a read depth &gt;30 and allele read frequency &gt;0.30 were filtered. We selected heterozygous nonsynonymous variants with frequency &lt;1% in the exome variant server, affecting the protein-coding sequence (nonsense, missense, frameshift, or essential splice-site) and predicted to be damaging by at least 1 of 2 in silico prediction tools (Sift, <ext-link ext-link-type="uri" xlink:href="http://sift.jcvi.org/">http://sift.jcvi.org/</ext-link>; PolyPhen-2, <ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link>). We followed the guidelines for assigning causality of sequence variants in human disease as outlined.<sup><xref ref-type="bibr" rid="R14">14</xref></sup> Coverage of <italic>GABRG2</italic> was satisfactory (&gt;250Ã) except for exon 6, which was subsequently analyzed by traditional Sanger sequencing. Filtered variants were validated by Sanger sequencing, and segregation was analyzed in all available family members. Impact of mutations was assessed with Alamut version 2.4.3 (Interactive Biosoftware). <italic>GABRG2</italic> mutations were mapped on the immature peptide, according to the current convention.<sup><xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R16">16</xref></sup> We compared the frequency of rare nonsynonymous <italic>GABRG2</italic> variants (including missense, nonsense, essential splice-site, in-frame Indels) identified in patients with epilepsy and those present in 33,370 European cases from the publicly available Exome Aggregation Consortium (ExAC) database (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>) using Fisher exact tests (accessed July 2015).</p>
</sec>
<sec id="s1-5">
<title>Linkage analysis.</title>
<p>Pairwise LOD scores were calculated using the MLINK program of the FASTLINK package version 4.1 assuming an autosomal dominant trait for FS with disease allele frequency of 0.01 and incomplete penetrance of 85%. Because the frequency of FS in the general population is approximately 2%â5%, we used a phenocopy rate of 3% as previously reported.<sup><xref ref-type="bibr" rid="R17">17</xref></sup> We considered as affected all individuals with FS.</p>
</sec>
<sec id="s1-6">
<title>CGH array.</title>
<p>CGH array was performed in the 43 probands of the Italian cohort using a custom 105K Agilent CGH array containing 44K backbone genome-wide probes and approximately 60K high-density probes spanning 440 genes encoding for ion channels (list available on request) according to previously described protocols and bioinformatics pipelines.<sup><xref ref-type="bibr" rid="R18">18</xref></sup></p>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>RESULTS</title>
<sec id="s2-1">
<title>Exome sequencing.</title>
<p>Exome sequencing revealed a pathogenic mutation in <italic>GABRG2</italic>. Clinical features of family A were described previously.<sup><xref ref-type="bibr" rid="R19">19</xref></sup> This large 5-generation French family included 9 individuals with seizures (<xref ref-type="table" rid="T1">table</xref>). All 9 patients presented simple FS in early childhood (age at onset range: 12 months to 3 years), 7 of 9 individuals subsequently developed focal epilepsy with EEG and clinical features strongly suggestive of TLE, and 1 patient had only generalized tonic-clonic seizures (GTCS). Brain MRI showed normal hippocampal architecture and volume on both sides in 5 patients. Interictal EEGs showed epileptiform abnormalities localized in the temporal lobe in 6 patients, and was normal in 1 patient (A/II-6) with FS only.</p>
<table-wrap id="T1" position="float">
<label>Table</label>
<caption>
<p>Clinical features of patients</p>
</caption>
<graphic xlink:href="NG2015000638TT1"></graphic>
<graphic xlink:href="NG2015000638TT1A"></graphic>
</table-wrap>
<p>We performed whole-exome sequencing on 3 affected family members (A/II-1, A/II-4, and A/II-9). Originally, a 20 cM spaced genome-wide microsatellite analysis was suggestive of a locus on chromosome 18qter and a probable second locus on chromosome 1q25-q31 with maximum pairwise LOD scores of 3.04 and 2.33, respectively.<sup><xref ref-type="bibr" rid="R19">19</xref></sup> We first focused the analysis on these 2 regions, then on the rest of the exome dataset. According to our filtering criteria, only 7 variants were common to all 3 siblings, but none of the corresponding genes (<italic>ABL2</italic>, <italic>BOD1L1</italic>, <italic>B3GALT4</italic>, <italic>EXO1</italic>, <italic>HERC4</italic>, <italic>OR5K1</italic>, or <italic>SSH2</italic>) were functionally candidate for epilepsy or expressed in the brain. We therefore subsequently restricted the analysis to the exome datasets of individuals A/II-1 and A/II-4, who belong to the same branch of the family. We identified a heterozygous deletion/insertion mutation (c.1206delinsTTCAT) in exon 9 of the Î³2 subunit of the GABA<sub>A</sub> receptor gene <italic>GABRG2</italic> gene (located on chromosome 5) in both A/II-1 and A/II-4. Sanger sequencing indicated that the p.Glu402fs*3 variant was segregated within all affected family members of the first branch, but was not present in individual A/II-9 (<xref ref-type="fig" rid="F1">figure 1</xref>). The variant created a frameshift at codon Glu402 leading to a new reading frame that ended in a stop codon 2 positions downstream (p.Glu402fs*3). Several arguments pointed toward the pathogenicity of the <italic>GABRG2</italic> variant in the family: (1) the <italic>GABRG2</italic> gene is known to be implicated in familial epilepsies; (2) this variant disrupts the reading frame leading to a loss-of-function mechanism, as previously reported for other mutations<sup><xref ref-type="bibr" rid="R16">16</xref></sup>; and (3) this truncating variant segregated among affected family members (apart from A/II-9). We therefore considered individual A/II-9 as a phenocopy. We reviewed the history of seizures of individual A/II-9, which consisted of few episodes of FS between ages 1 and 4 years. During adolescence, she presented a unique probable focal seizure with loss of consciousness and gestural automatisms and 2 GTCS (1 nocturnal and 1 diurnal), over a period of 6 months (period of emotional stress). We also noted that the mother of individual A/II-9 was asymptomatic, as well as her sister and her children, which confirms that this branch of the family was unlikely to bear the same genetic defect.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Pedigrees of the families with <italic>GABRG2</italic> mutation segregation</title>
<p>Pedigrees of family A (p.Glu402fs*3), family B (p.Arg136*), family C (p.Val462fs*33), family D (p.Pro59fs*12), family E (p.Met199Val), and family F (<italic>GABRG2</italic> deletion) are represented. The respective <italic>GABRG2</italic> mutations (NM_000816.3) are indicated. Individuals who carry a heterozygous <italic>GABRG2</italic> mutation are denoted by m/+, and those negative for mutations are denoted by +/+. Arrows indicate index cases.</p>
</caption>
<graphic xlink:href="NG2015000638FF1"></graphic>
</fig>
</sec>
<sec id="s2-2">
<title>Mutational screening of <italic>GABRG2</italic> in the follow-up cohort.</title>
<p>Sequencing of <italic>GABRG2</italic> was performed in a follow-up cohort of 64 probands from French families and 43 from Italian families with FS with or without epilepsy (<xref ref-type="table" rid="T1">table</xref> and <xref ref-type="fig" rid="F1">figure 1</xref>). CGH array was performed in the 43 probands of the Italian families.</p>
<p>Family B was a large multigenerational family, comprising 10 affected individuals, among which 7 patients had simple FS occurring between age 13 and 24 months. All patients had normal development. Two half brothers (B/IV-7 and B/IV-9) presented focal seizures in childhood with no history of FS. EEG and clinical features suggested benign rolandic epilepsy. Patient B/IV-5 presented at age 6 years a single brief afebrile GTCS 2 days after a fall while cycling with loss of consciousness of 10â15 minutes, suggesting a possible posttraumatic event. After the fall, her brain CT scan was normal and EEG 1 month after the accident was normal; she received no treatment. Gene panel sequencing identified a heterozygous nonsense mutation (c.406C&gt;T, p.Arg136*, exon 4) in <italic>GABRG2</italic> in the index case (B/III-10). Subsequent Sanger sequencing revealed that the p.Arg136* mutation segregated with the FS component and was absent in the 2 individuals with focal seizures without FS (B/IV-7 and B/IV-9) and in individual B/IV-5 with a single GTCS and no FS.</p>
<p>Family C consisted of 5 affected individuals over 4 generations. Four patients (C/II-1, C/III-1, C/IV-1, and C/IV-2) had simple FS with an age at onset between 10 and 14 months. No information was available on the epilepsy type of the deceased patient (C/I-1) of the first generation. FS spontaneously remitted before age 3 years, except in individual C/IV-1, whose FS lasted up to age 8 years, therefore designated as FS+. None of the patients had subsequent epilepsy. Sequencing of the index case (C/III-1) revealed a heterozygous single base deletion (c.1382delG) in exon 9 of <italic>GABRG2,</italic> also present in his affected sons, but not in his father (C/II-1), which is another example of phenocopy. DNA of his mother was not available for genetic studies to investigate the mode of transmission of the mutation. This variant creates a frameshift, resulting in loss of the last 6 C-terminal amino acids and incorporation of 32 extra amino acids with a final predicted peptide of 493 amino acids instead of 467 (p.Val462fs*33).</p>
<p>Family D comprised 5 patients with FS or epilepsy. Medical reports were not available for review, but telephonic interviews with family members revealed that 3 of them (D/III-1, D/III-5, and D/III-7) had a history of FS, 2 of whom developed subsequent tonic-clonic seizures (TCS) and episodes of loss of consciousness (D/III-1 and D/III-7); 2 other family members had TCS (D/II-2) or TCS and episodes of loss of consciousness, both without a known history of FS (D/II-5). Insufficient information was available to classify the epilepsy in the family as generalized or focal. A c.174_175delinsA (p.Pro59fs*12) mutation in exon 2 of <italic>GABRG2</italic> leading to a frameshift starting at codon Pro59 followed by a premature stop codon after 12 amino acids segregated in the 3 patients whose DNA was available.</p>
<p>Family E comprised a father and 2 daughters with FS, followed by early-onset absence seizures and GTCS. Development was normal in all 3 family members. Despite a high seizure frequency, especially in the father, all became seizure-free with valproate. A missense variant, c.595A&gt;G/p.Met199Val in exon 5 of <italic>GABRG2</italic>, was found in the 3 patients. The variant was predicted deleterious by Sift, disease-causing by MutationTaster, and probably damaging by PolyPhen-2. The p.Met199Val mutation is located in the N-terminal extracellular loop of the protein (<xref ref-type="fig" rid="F2">figure 2</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Schematic representation of the Î³2 subunit of the GABA<sub>A</sub> receptor with the position of all reported point mutations</title>
<p>Disease-causing point mutations in <italic>GABRG2</italic> include 8 missense mutations,<sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup> 4 nonsense mutations,<sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R41">41</xref></sup> 4 frameshifts,<sup><xref ref-type="bibr" rid="R25">25</xref></sup> and 2 splice-sites.<sup><xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup> Mutations indicated by a blue star were identified in this study; those indicated by a red star were previously reported. All mutations are reported on the immature peptide. Protein structure was designed according to UniProt database information (NP_000807.2).</p>
</caption>
<graphic xlink:href="NG2015000638FF2"></graphic>
</fig>
<p>An intragenic deletion in the proband of Italian family F and his affected mother was identified at 5q34 spanning 145K at chr5, 160.631.665â161.067.144, and affecting coding exons 1â4 of <italic>GABRG2</italic>. The proband (F/II-1) was an 8-year-old boy who had recurrent episodes of simple FS between ages 12 and 36 months, which remitted spontaneously. From age 5 years, he developed absence seizures and 2 GTCS, successfully treated with valproate. His mother (F/I-1) had 4 episodes of simple FS during her first 2 years of life. Both individuals had normal cognition. No additional affected relatives were reported.</p>
<p>Gene panel sequencing performed in the probands of family B, C, D, and E did not identify other rare variants in known epilepsy genes targeted in our panel. None of the <italic>GABRG2</italic> mutations of this study were reported in the Exome Aggregation Consortium (ExAC) database, which includes the 1000 Genomes project database and the 6,503 exomes listed in the exome variant server. Although we acknowledge that the <italic>p</italic> value might be overestimated because of a lower coverage of exons 3 and 6 in ExAC control individuals, we observed a significant enrichment of rare nonsynonymous <italic>GABRG2</italic> variants in our cohort of patients (6/108, 5.6%) compared with individuals of European ancestry from the ExAC browser (73/33,370 (0.22%), <italic>p</italic> &lt; 2.2 Ã 10<sup>â7</sup>). To further demonstrate the causality of the <italic>GABRG2</italic> variants in the FS phenotype by linkage analysis, we calculated 2-point LOD scores in the 6 families. The sum of the maximal pairwise LOD scores was 3.02, indicating significant likelihood that the <italic>GABRG2</italic> variants are causal.</p>
<p>Four variants (p.Glu402fs*3, p.Arg136*, p.Val462fs*33, and p.Pro59fs*12) were securely considered pathogenic because they introduced an erroneous stop codon in the reading frame. While p.Arg136* and p.Pro59fs*12 were predicted to be degraded by the nonsense-mediated-decay system (NMD), p.Glu402fs*3 and p.Val462fs*33, located in the last exon of <italic>GABRG2</italic>, may escape the NMD and lead to a truncated or a longer Î³2 subunit, respectively. The p.Met199Val missense variant was likely to be pathogenic according to 3 in silico prediction tools. All mutations were novel except p.Arg136*, which was previously reported in a family with GEFS+, learning difficulties, and autism spectrum disorder, although it was segregated mostly with the FS component.<sup><xref ref-type="bibr" rid="R20">20</xref></sup></p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>DISCUSSION</title>
<p>GABA<sub>A</sub> receptors mediate fast inhibitory synaptic transmission in the CNS. GABA<sub>A</sub> receptors are heteropentameric ligand-gated chloride channels combining 5 of 19 different subunits. The most common configuration in mammals requires 1 Î³2 subunit in association with 2 Î±1-3 and 2 Î²2/3 subunits.<sup><xref ref-type="bibr" rid="R21">21</xref></sup></p>
<p>Up to now, mutations in the <italic>GABRG2</italic> gene, encoding the GABA<sub>A</sub> receptor Î³2 subunit, have been reported in a subset of families, but their prevalence remained unknown. In the literature, individuals with <italic>GABRG2</italic> mutations presented a variety of phenotypes ranging from pure FS,<sup><xref ref-type="bibr" rid="R22">22</xref></sup> FS+ or FS and generalized epilepsy (absence seizures or GTCS),<sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R23">23</xref><xref ref-type="bibr" rid="R24">â</xref><xref ref-type="bibr" rid="R29">29</xref></sup> GTCS without FS,<sup><xref ref-type="bibr" rid="R30">30</xref></sup> FS and rolandic epilepsy,<sup><xref ref-type="bibr" rid="R31">31</xref></sup> to possibly Dravet syndrome (a nonsense mutation was reported in dizygotic twins with Dravet syndrome and their healthy father).<sup><xref ref-type="bibr" rid="R32">32</xref></sup></p>
<p>In this study, we assessed the frequency of <italic>GABRG2</italic> mutations in a large cohort of families with FS and reported pathogenic mutations in 6/108 (5.6%) families. First, we identified a <italic>GABRG2</italic> disease-causing mutation (p.Glu402fs*3) in a multiplex family with FS and TLE, in which linkage analysis previously suggested a possible digenic inheritance on 1q25-q31 and 18qter.<sup><xref ref-type="bibr" rid="R19">19</xref></sup> However, with the finding of a clear pathogenic mutation in <italic>GABRG2</italic>, leading to the introduction of a premature stop codon (p.Glu402fs*3), both loci were unlikely to cause the phenotype. This study provides a clear example of the limitation of linkage analysis and how phenocopies can distort linkage results (1 affected member of the large family did not carry the <italic>GABRG2</italic> mutation). Unbiased next-generation sequencing approaches will undoubtedly unveil additional erroneous genetic claims in the literature. In the follow-up cohort consisting of 107 families with FS (with or without subsequent epilepsy), we identified 2 other frameshift mutations (p.Val462fs*33 and p.Pro59fs*12), 1 nonsense mutation (p.Arg136*), 1 missense mutation (p.Met199Val), and 1 deletion (exons 1â4) in the <italic>GABRG2</italic> gene. Most patients carrying a <italic>GABRG2</italic> mutation had a reported history of FS (22/23), associated with TLE in 1 family (family A), generalized epilepsy with absences and GTCS in 2 families (families E and F), and undefined epilepsy with TCS and episodes of loss of consciousness in 1 family (family D). <italic>GABRG2</italic> mutations segregated predominantly with FS, indicating that <italic>GABRG2</italic> mutations are drivers of the FS phenotype, rather than epilepsy. As expected with common traits, several affected family members did not carry a <italic>GABRG2</italic> mutation: 3 family members without a history of FS (B/IV-5, B/IV-7, and B/IV-9) and 2 phenocopies (individuals A/II-9 and C/II-1). Overall, the penetrance of <italic>GABRG2</italic> mutations was high in our cohort, with only one asymptomatic carrier (individual A/I-2). It should be noted though that a history of FS may have been underreported in this generation. The relatively high frequency (5.6%) of <italic>GABRG2</italic> mutations compared with previously published data<sup><xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R30">30</xref></sup> is most probably linked to the fact that FS segregating as an autosomal dominant trait was a study inclusion criterion. Additional genetic or epigenetic modifiers probably determine the associated epilepsy component, which can result either in no subsequent epilepsy or in the development of both generalized and focal seizures. Consistent with this hypothesis, 2 <italic>Gabrg2</italic> knock-in (p.Arg82Gln) mouse models established in 2 different mouse strains exhibited similar temperature-seizure susceptibilities, mimicking the FS phenotype, whereas the epilepsy phenotype was only present in 1 strain.<sup><xref ref-type="bibr" rid="R33">33</xref></sup> This suggested that FS are less sensitive to genetic background than the associated epileptic phenotypes. An emerging question is how to explain the link between FS and GABAergic defects. Reports have shown that the GEFS+-causing mutation p.Lys328Met affects the membrane dynamics and postsynaptic aggregation of the GABA<sub>A</sub> mutant receptor in conditions of increased temperature, confirming the susceptibility to temperature.<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R35">35</xref></sup></p>
<p>Currently, a total of 19 different <italic>GABRG2</italic> disease-causing mutations have been reported (including this study), consisting of 8 missense, 4 nonsense, 4 frameshifts, 2 splice-sites, and 1 deletion (<xref ref-type="fig" rid="F2">figure 2</xref>). The high rate of truncating mutations (11/19, 57%), strengthened by this study, strongly suggests that haploinsufficiency resulting in loss of function of GABA<sub>A</sub> receptor Î³2 subunit underlies <italic>GABRG2</italic>-related seizure phenotypes. This is concordant with numerous in vitro functional assays showing that <italic>GABRG2</italic> mutations resulted in mRNA degradation by NMD, the translation of proteins retained in the endoplasmic reticulum with impaired surface-expression, or dysfunctional channel properties of GABA<sub>A</sub> receptors<sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R36">36</xref><xref ref-type="bibr" rid="R37">â</xref><xref ref-type="bibr" rid="R38">38</xref></sup> (for review, see <xref ref-type="bibr" rid="R15">references 15 and 16</xref>). However, 2 recent in vivo studies using Gln390*-<italic>Gabrg2</italic> knock-in mice showed that dominant-negative effects on wild-type Î³2 and partner subunits also certainly participated to reduce GABA-evoked currents.<sup><xref ref-type="bibr" rid="R33">33</xref>,<xref ref-type="bibr" rid="R39">39</xref></sup> A reduction in cortical synaptic GABAergic inhibition was confirmed to cause seizures in another p.Arg82Gln-<italic>Gabrg2</italic> knock-in mouse model.<sup><xref ref-type="bibr" rid="R40">40</xref></sup> Nevertheless, the link between dysfunctional GABA<sub>A</sub> receptors and seizures is still poorly understood.</p>
<p>Mutations in <italic>GABRG2</italic> are more frequent than initially reported, and screening of the gene should be included when considering genetic testing in families with an overall mild phenotype consisting of FS with or without epilepsy.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGMENT</title>
<p>The authors thank the patients and families for their participation in the study and the sequencing platform of ICM (Y. Marie), the bioinformatics/biostatistics core facility of ICM (J. Guegan), the DNA and cell bank of ICM (C. Dussert and S. Forlani) and Genethon (J. Debusne) for providing technical assistance, and J. Lemke for discussion.</p>
</ack>
<sec sec-type="contributions">
<title>AUTHOR CONTRIBUTIONS</title>
<p content-type="contributions">M. Boillot: drafting the manuscript, analysis and interpretation of genetic data. M. Morin-Brureau: acquisition, analysis, and interpretation of exome data. F. Picard: acquisition and interpretation of clinical data. S. Weckhuysen: interpretation of clinical and genetic data, drafting the manuscript. V. Lambrecq: acquisition and interpretation of clinical data. C. Minetti: acquisition of clinical data. P. Striano: acquisition and interpretation of clinical and genetic data. F. Zara: acquisition and interpretation of clinical and genetic data. M. Iacomino: acquisition and interpretation of genetic data. S. Ishida: acquisition of genetic data. I. An-Gourfinkel: acquisition and interpretation of clinical data. M. Daniau: acquisition of genetic data. K. Hardies: LOD score calculation, M. Baulac: supervising the acquisition and interpretation of clinical data. O. Dulac: supervising the acquisition and interpretation of clinical data. E. Leguern: study design. R. Nabbout: acquisition and interpretation of clinical data and study design. S. Baulac: analysis and interpretation of genetic data, study supervision, drafting the manuscript and obtaining funding. All authors critically reviewed and approved the final manuscript.</p>
</sec>
<sec sec-type="funding">
<title>STUDY FUNDING</title>
<p content-type="funding">Supported by the French program âInvestissements d'avenirâ (ANR-10-IAIHU-06), the Fondation FranÃ§aise pour la Recherche sur l'Epilepsie (FFRE), and the Association de Recherche sur la GÃ©nÃ©tique des Epilepsies (ARGE).</p>
</sec>
<sec sec-type="disclosure">
<title>DISCLOSURE</title>
<p content-type="disclosure">M. Boillot has received research support from the Ligue FranÃ§aise contre l'Epilepsie (LFCE). M. Morin-Brureau reports no disclosures. F. Picard has received a grant from the <funding-source>Swiss National Foundation</funding-source> (No. 320030-127608). S. Weckhuysen has received research support from the French program âInvestissements d'avenirâ (ANR-10-IAIHU-06). V. Lambrecq has received research support from the French program âInvestissements d'avenirâ (ANR-10-IAIHU-06). C. Minetti reports no disclosures. P. Striano has received research support from the <funding-source>Italian ministry of health</funding-source> (project GR-2009â1473821). F. Zara and M. Iacomino report no disclosures. S. Ishida has received research support from the <funding-source>Japan Society for the Promotion of Science (JSPS)</funding-source>. I. An-Gourfinkel and M. Daniau report no disclosures. K. Hardies has been a PhD fellow of the Institute for Science and Technology (IWT)-Flanders. M. Baulac has served on the scientific advisory boards of UCB, Eisai, GSK, SAGE, GW Pharmaceuticals; has received travel support and/or honoraria from UCB and Eisai GSK; and has been a consultant for UCB, Eisai, and GSK. O. Dulac reports no disclosures. E. Leguern has received research support from Program âInvestissements d'avenirâ ANR-10-IAIHU-0, INSERM, and Assistance Publique des HÃ´pitaux de Paris. R. Nabbout has served on the scientific advisory board for Novartis; has received travel support from Shire and speaker honoraria from Novartis, Cyberonics, and Eisai; and has served on the editorial board for <italic>Epilepsia.</italic> S. Baulac has received research support from Program âInvestissements d'avenirâ ANR-10-IAIHU-06 and Carnot Institute (No. CT010). Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000035">Neurology.org/ng</ext-link> for full disclosure forms.</p>
</sec>
<glossary>
<title>GLOSSARY</title>
<def-list>
<def-item>
<term id="G1">FS</term>
<def>
<p>febrile seizures</p>
</def>
</def-item>
<def-item>
<term id="G2">GEFS+</term>
<def>
<p>genetic epilepsy with febrile seizures plus</p>
</def>
</def-item>
<def-item>
<term id="G3">GTCS</term>
<def>
<p>generalized tonic-clonic seizures</p>
</def>
</def-item>
<def-item>
<term id="G4">NMD</term>
<def>
<p>nonsense-mediated-decay system</p>
</def>
</def-item>
<def-item>
<term id="G5">TCS</term>
<def>
<p>tonic-clonic seizures</p>
</def>
</def-item>
<def-item>
<term id="G6">TLE</term>
<def>
<p>temporal lobe epilepsy</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>KB</given-names></name><name><surname>Ellenberg</surname><given-names>JH</given-names></name></person-group>
<article-title>Predictors of epilepsy in children who have experienced febrile seizures</article-title>. <source/>N Engl J Med
<year>1976</year>;<volume>295</volume>:<fpage>1029</fpage>â<lpage>1033</lpage>.<pub-id pub-id-type="pmid">972656</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>WG</given-names></name><name><surname>Kugler</surname><given-names>SL</given-names></name><name><surname>Stenroos</surname><given-names>ES</given-names></name><etal></etal></person-group>
<article-title>Pedigree analysis in families with febrile seizures</article-title>. <source/>Am J Med Genet
<year>1996</year>;<volume>61</volume>:<fpage>345</fpage>â<lpage>352</lpage>.<pub-id pub-id-type="pmid">8834046</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saghazadeh</surname><given-names>A</given-names></name><name><surname>Mastrangelo</surname><given-names>M</given-names></name><name><surname>Rezaei</surname><given-names>N</given-names></name></person-group>
<article-title>Genetic background of febrile seizures</article-title>. <source/>Rev Neurosci
<year>2014</year>;<volume>25</volume>:<fpage>129</fpage>â<lpage>161</lpage>.<pub-id pub-id-type="pmid">24399675</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Zhang</surname><given-names>YH</given-names></name><name><surname>Jansen</surname><given-names>FE</given-names></name><name><surname>Dibbens</surname><given-names>L</given-names></name></person-group>
<article-title>Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?</article-title>
<source/>Brain Dev
<year>2009</year>;<volume>31</volume>:<fpage>394</fpage>â<lpage>400</lpage>.<pub-id pub-id-type="pmid">19203856</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>RH</given-names></name><name><surname>Wang</surname><given-names>DW</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B</article-title>. <source/>Nat Genet
<year>1998</year>;<volume>19</volume>:<fpage>366</fpage>â<lpage>370</lpage>.<pub-id pub-id-type="pmid">9697698</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escayg</surname><given-names>A</given-names></name><name><surname>MacDonald</surname><given-names>BT</given-names></name><name><surname>Meisler</surname><given-names>MH</given-names></name><name><surname>Baulac</surname><given-names>S</given-names></name><name><surname>Huberfeld</surname><given-names>G</given-names></name><name><surname>An-Gourfinkel</surname><given-names>I</given-names></name></person-group>
<article-title>Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2</article-title>. <source/>Nat Genet
<year>2000</year>;<volume>24</volume>:<fpage>343</fpage>â<lpage>345</lpage>.<pub-id pub-id-type="pmid">10742094</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baulac</surname><given-names>S</given-names></name><name><surname>Huberfeld</surname><given-names>G</given-names></name><name><surname>Gourfinkel-An</surname><given-names>I</given-names></name><name><surname>Mitropoulou</surname><given-names>G</given-names></name><name><surname>Beranger</surname><given-names>A</given-names></name><name><surname>Prud'homme</surname><given-names>JF</given-names></name></person-group>
<article-title>First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene</article-title>. <source/>Nat Genet
<year>2001</year>;<volume>28</volume>:<fpage>46</fpage>â<lpage>48</lpage>.<pub-id pub-id-type="pmid">11326274</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baulac</surname><given-names>S</given-names></name><name><surname>Gourfinkel-An</surname><given-names>I</given-names></name><name><surname>Nabbout</surname><given-names>R</given-names></name><name><surname>Huberfeld</surname><given-names>G</given-names></name><name><surname>Serratosa</surname><given-names>J</given-names></name><name><surname>Leguern</surname><given-names>E</given-names></name></person-group>
<article-title>Fever, genes, and epilepsy</article-title>. <source/>Lancet Neurol
<year>2004</year>;<volume>3</volume>:<fpage>421</fpage>â<lpage>430</lpage>.<pub-id pub-id-type="pmid">15207799</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audenaert</surname><given-names>D</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>De Jonghe</surname><given-names>P</given-names></name></person-group>
<article-title>Genes and loci involved in febrile seizures and related epilepsy syndromes</article-title>. <source/>Hum Mutat
<year>2006</year>;<volume>27</volume>:<fpage>391</fpage>â<lpage>401</lpage>.<pub-id pub-id-type="pmid">16550559</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escayg</surname><given-names>A</given-names></name><name><surname>Goldin</surname><given-names>AL</given-names></name></person-group>
<article-title>Sodium channel SCN1A and epilepsy: mutations and mechanisms</article-title>. <source/>Epilepsia
<year>2010</year>;<volume>51</volume>:<fpage>1650</fpage>â<lpage>1658</lpage>.<pub-id pub-id-type="pmid">20831750</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>J</given-names></name><name><surname>Siekierska</surname><given-names>A</given-names></name><name><surname>Langlois</surname><given-names>M</given-names></name><name><surname>May</surname><given-names>P</given-names></name><name><surname>Huneau</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>F</given-names></name></person-group>
<article-title>Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes</article-title>. <source/>Nat Genet
<year>2014</year>;<volume>46</volume>:<fpage>1327</fpage>â<lpage>1332</lpage>.<pub-id pub-id-type="pmid">25362483</pub-id></mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Picard</surname><given-names>F</given-names></name><name><surname>Rudolf</surname><given-names>G</given-names></name><name><surname>NoÃ©</surname><given-names>E</given-names></name><name><surname>Achaz</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name></person-group>
<article-title>Mutations of DEPDC5 cause autosomal dominant focal epilepsies</article-title>. <source/>Nat Genet
<year>2013</year>;<volume>45</volume>:<fpage>552</fpage>â<lpage>555</lpage>.<pub-id pub-id-type="pmid">23542701</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madia</surname><given-names>F</given-names></name><name><surname>Gennaro</surname><given-names>E</given-names></name><name><surname>Cecconi</surname><given-names>M</given-names></name><name><surname>Buti</surname><given-names>D</given-names></name><name><surname>Capovilla</surname><given-names>G</given-names></name><name><surname>Dalla Bernardina</surname><given-names>B</given-names></name></person-group>
<article-title>No evidence of GABRG2 mutations in severe myoclonic epilepsy of infancy</article-title>. <source/>Epilepsy Res
<year>2003</year>;<volume>53</volume>:<fpage>196</fpage>â<lpage>200</lpage>.<pub-id pub-id-type="pmid">12694927</pub-id></mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>Manolio</surname><given-names>TA</given-names></name><name><surname>Dimmock</surname><given-names>DP</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name></person-group>
<article-title>Guidelines for investigating causality of sequence variants in human disease</article-title>. <source/>Nature
<year>2014</year>;<volume>508</volume>:<fpage>469</fpage>â<lpage>476</lpage>.<pub-id pub-id-type="pmid">24759409</pub-id></mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>RL</given-names></name><name><surname>Kang</surname><given-names>JQ</given-names></name><name><surname>Gallagher</surname><given-names>MJ</given-names></name></person-group>
<article-title>GABAA receptor subunit mutations and genetic epilepsies</article-title>. In: <person-group person-group-type="editor"><name><surname>Noebels</surname><given-names>JL</given-names></name><name><surname>Avoli</surname><given-names>M</given-names></name><name><surname>Rogawski</surname><given-names>MA</given-names></name><etal></etal></person-group>, eds. <source/>Jasper's Basic Mechanisms of the Epilepsies, <edition>4th ed</edition>
<publisher-loc>Bethesda</publisher-loc>: <publisher-name>National Center for Biotechnology Information</publisher-name>; <year>2012</year>.</mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirose</surname><given-names>S</given-names></name></person-group>
<article-title>Mutant GABA(A) receptor subunits in genetic (idiopathic) epilepsy</article-title>. <source/>Prog Brain Res
<year>2014</year>;<volume>213</volume>:<fpage>55</fpage>â<lpage>85</lpage>.<pub-id pub-id-type="pmid">25194483</pub-id></mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baulac</surname><given-names>S</given-names></name><name><surname>Gourfinkel-An</surname><given-names>I</given-names></name><name><surname>Picard</surname><given-names>F</given-names></name><name><surname>Rosenberg-Bourgin</surname><given-names>M</given-names></name><name><surname>Prud'homme</surname><given-names>JF</given-names></name><name><surname>Baulac</surname><given-names>M</given-names></name></person-group>
<article-title>A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33</article-title>. <source/>Am J Hum Genet
<year>1999</year>;<volume>65</volume>:<fpage>1078</fpage>â<lpage>1085</lpage>.<pub-id pub-id-type="pmid">10486327</pub-id></mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Striano</surname><given-names>P</given-names></name><name><surname>Coppola</surname><given-names>A</given-names></name><name><surname>Paravidino</surname><given-names>R</given-names></name><name><surname>Malacarne</surname><given-names>M</given-names></name><name><surname>Gimelli</surname><given-names>S</given-names></name><name><surname>Robbiano</surname><given-names>A</given-names></name></person-group>
<article-title>Clinical significance of rare copy number variations in epilepsy: a case-control survey using microarray-based comparative genomic hybridization</article-title>. <source/>Arch Neurol
<year>2012</year>;<volume>69</volume>:<fpage>322</fpage>â<lpage>330</lpage>.<pub-id pub-id-type="pmid">22083797</pub-id></mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baulac</surname><given-names>S</given-names></name><name><surname>Picard</surname><given-names>F</given-names></name><name><surname>Herman</surname><given-names>A</given-names></name><name><surname>Feingold</surname><given-names>J</given-names></name><name><surname>Genin</surname><given-names>E</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name></person-group>
<article-title>Evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosomes 18qter and 1q25-q31</article-title>. <source/>Ann Neurol
<year>2001</year>;<volume>49</volume>:<fpage>786</fpage>â<lpage>792</lpage>.<pub-id pub-id-type="pmid">11409431</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>AJ</given-names></name><name><surname>Kang</surname><given-names>JQ</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Pickrell</surname><given-names>WO</given-names></name><name><surname>Cushion</surname><given-names>TD</given-names></name><name><surname>Davies</surname><given-names>JS</given-names></name></person-group>
<article-title>A novel GABRG2 mutation, p.R136*, in a family with GEFS+ and extended phenotypes</article-title>. <source/>Neurobiol Dis
<year>2014</year>;<volume>64</volume>:<fpage>131</fpage>â<lpage>141</lpage>.<pub-id pub-id-type="pmid">24407264</pub-id></mixed-citation>
</ref>
<ref id="R21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrant</surname><given-names>M</given-names></name><name><surname>Nusser</surname><given-names>Z</given-names></name></person-group>
<article-title>Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors</article-title>. <source/>Nat Rev Neurosci
<year>2005</year>;<volume>6</volume>:<fpage>215</fpage>â<lpage>229</lpage>.<pub-id pub-id-type="pmid">15738957</pub-id></mixed-citation>
</ref>
<ref id="R22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audenaert</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>E</given-names></name><name><surname>Claeys</surname><given-names>KG</given-names></name><name><surname>Claes</surname><given-names>L</given-names></name><name><surname>Deprez</surname><given-names>L</given-names></name><name><surname>Suls</surname><given-names>A</given-names></name></person-group>
<article-title>A novel GABRG2 mutation associated with febrile seizures</article-title>. <source/>Neurology
<year>2006</year>;<volume>67</volume>:<fpage>687</fpage>â<lpage>690</lpage>.<pub-id pub-id-type="pmid">16924025</pub-id></mixed-citation>
</ref>
<ref id="R23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group>
<article-title>SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus</article-title>. <source/>J Hum Genet
<year>2008</year>;<volume>53</volume>:<fpage>769</fpage>â<lpage>774</lpage>.<pub-id pub-id-type="pmid">18566737</pub-id></mixed-citation>
</ref>
<ref id="R24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachance-Touchette</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Meloche</surname><given-names>C</given-names></name><name><surname>Kinirons</surname><given-names>P</given-names></name><name><surname>Lapointe</surname><given-names>L</given-names></name><name><surname>Lacasse</surname><given-names>H</given-names></name></person-group>
<article-title>Novel alpha1 and gamma2 GABAA receptor subunit mutations in families with idiopathic generalized epilepsy</article-title>. <source/>Eur J Neurosci
<year>2011</year>;<volume>34</volume>:<fpage>237</fpage>â<lpage>249</lpage>.<pub-id pub-id-type="pmid">21714819</pub-id></mixed-citation>
</ref>
<ref id="R25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Mei</surname><given-names>D</given-names></name><name><surname>Freri</surname><given-names>E</given-names></name><name><surname>Hernandez</surname><given-names>CC</given-names></name><name><surname>Granata</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name></person-group>
<article-title>Impaired surface alphabetagamma GABA(A) receptor expression in familial epilepsy due to a GABRG2 frameshift mutation</article-title>. <source/>Neurobiol Dis
<year>2013</year>;<volume>50</volume>:<fpage>135</fpage>â<lpage>141</lpage>.<pub-id pub-id-type="pmid">23069679</pub-id></mixed-citation>
</ref>
<ref id="R26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvill</surname><given-names>GL</given-names></name><name><surname>Heavin</surname><given-names>SB</given-names></name><name><surname>Yendle</surname><given-names>SC</given-names></name><name><surname>McMahon</surname><given-names>JM</given-names></name><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Cook</surname><given-names>J</given-names></name></person-group>
<article-title>Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1</article-title>. <source/>Nat Genet
<year>2013</year>;<volume>45</volume>:<fpage>825</fpage>â<lpage>830</lpage>.<pub-id pub-id-type="pmid">23708187</pub-id></mixed-citation>
</ref>
<ref id="R27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>RH</given-names></name><name><surname>Marini</surname><given-names>C</given-names></name><name><surname>Petrou</surname><given-names>S</given-names></name><name><surname>Harkin</surname><given-names>LA</given-names></name><name><surname>Bowser</surname><given-names>DN</given-names></name><name><surname>Panchal</surname><given-names>RG</given-names></name></person-group>
<article-title>Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures</article-title>. <source/>Nat Genet
<year>2001</year>;<volume>28</volume>:<fpage>49</fpage>â<lpage>52</lpage>.<pub-id pub-id-type="pmid">11326275</pub-id></mixed-citation>
</ref>
<ref id="R28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kananura</surname><given-names>C</given-names></name><name><surname>Haug</surname><given-names>K</given-names></name><name><surname>Sander</surname><given-names>T</given-names></name><name><surname>Runge</surname><given-names>U</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Hallmann</surname><given-names>K</given-names></name></person-group>
<article-title>A splice-site mutation in GABRG2 associated with childhood absence epilepsy and febrile convulsions</article-title>. <source/>Arch Neurol
<year>2002</year>;<volume>59</volume>:<fpage>1137</fpage>â<lpage>1141</lpage>.<pub-id pub-id-type="pmid">12117362</pub-id></mixed-citation>
</ref>
<ref id="R29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkin</surname><given-names>LA</given-names></name><name><surname>Bowser</surname><given-names>DN</given-names></name><name><surname>Dibbens</surname><given-names>LM</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Phillips</surname><given-names>F</given-names></name><name><surname>Wallace</surname><given-names>RH</given-names></name></person-group>
<article-title>Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus</article-title>. <source/>Am J Hum Genet
<year>2002</year>;<volume>70</volume>:<fpage>530</fpage>â<lpage>536</lpage>.<pub-id pub-id-type="pmid">11748509</pub-id></mixed-citation>
</ref>
<ref id="R30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>MC</given-names></name><name><surname>Ishii</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Morita</surname><given-names>K</given-names></name></person-group>
<article-title>Mutational analysis of GABRG2 in a Japanese cohort with childhood epilepsies</article-title>. <source/>J Hum Genet
<year>2010</year>;<volume>55</volume>:<fpage>375</fpage>â<lpage>378</lpage>.<pub-id pub-id-type="pmid">20485450</pub-id></mixed-citation>
</ref>
<ref id="R31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinthaler</surname><given-names>EM</given-names></name><name><surname>Dejanovic</surname><given-names>B</given-names></name><name><surname>Lal</surname><given-names>D</given-names></name><name><surname>Semtner</surname><given-names>M</given-names></name><name><surname>Merkler</surname><given-names>Y</given-names></name><name><surname>Reinhold</surname><given-names>A</given-names></name></person-group>
<article-title>Rare variants in gamma-aminobutyric acid type A receptor genes in rolandic epilepsy and related syndromes</article-title>. <source/>Ann Neurol
<year>2015</year>;<volume>77</volume>:<fpage>972</fpage>â<lpage>986</lpage>.<pub-id pub-id-type="pmid">25726841</pub-id></mixed-citation>
</ref>
<ref id="R32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>A</given-names></name><name><surname>Kanaumi</surname><given-names>T</given-names></name><name><surname>Sohda</surname><given-names>M</given-names></name><name><surname>Misumi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Kakinuma</surname><given-names>N</given-names></name></person-group>
<article-title>Association of nonsense mutation in GABRG2 with abnormal trafficking of GABAA receptors in severe epilepsy</article-title>. <source/>Epilepsy Res
<year>2014</year>;<volume>108</volume>:<fpage>420</fpage>â<lpage>432</lpage>.<pub-id pub-id-type="pmid">24480790</pub-id></mixed-citation>
</ref>
<ref id="R33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>CA</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Phillips</surname><given-names>AM</given-names></name><name><surname>Low</surname><given-names>J</given-names></name><name><surname>Berkovic</surname><given-names>SF</given-names></name><name><surname>Luscher</surname><given-names>B</given-names></name></person-group>
<article-title>Multiple molecular mechanisms for a single GABAA mutation in epilepsy</article-title>. <source/>Neurology
<year>2013</year>;<volume>80</volume>:<fpage>1003</fpage>â<lpage>1008</lpage>.<pub-id pub-id-type="pmid">23408872</pub-id></mixed-citation>
</ref>
<ref id="R34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eugene</surname><given-names>E</given-names></name><name><surname>Depienne</surname><given-names>C</given-names></name><name><surname>Baulac</surname><given-names>S</given-names></name><name><surname>Baulac</surname><given-names>M</given-names></name><name><surname>Fritschy</surname><given-names>JM</given-names></name><name><surname>Le Guern</surname><given-names>E</given-names></name></person-group>
<article-title>GABA(A) receptor gamma 2 subunit mutations linked to human epileptic syndromes differentially affect phasic and tonic inhibition</article-title>. <source/>J Neurosci
<year>2007</year>;<volume>27</volume>:<fpage>14108</fpage>â<lpage>14116</lpage>.<pub-id pub-id-type="pmid">18094250</pub-id></mixed-citation>
</ref>
<ref id="R35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouthour</surname><given-names>W</given-names></name><name><surname>Leroy</surname><given-names>F</given-names></name><name><surname>Emmanuelli</surname><given-names>C</given-names></name><name><surname>Carnaud</surname><given-names>M</given-names></name><name><surname>Dahan</surname><given-names>M</given-names></name><name><surname>Poncer</surname><given-names>JC</given-names></name></person-group>
<article-title>A human mutation in Gabrg2 associated with generalized epilepsy alters the membrane dynamics of GABAA receptors</article-title>. <source/>Cereb Cortex
<year>2012</year>;<volume>22</volume>:<fpage>1542</fpage>â<lpage>1553</lpage>.<pub-id pub-id-type="pmid">21908847</pub-id></mixed-citation>
</ref>
<ref id="R36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>CC</given-names></name></person-group>
<article-title>The GABRG2 nonsense mutation, Q40X, associated with Dravet syndrome activated NMD and generated a truncated subunit that was partially rescued by aminoglycoside-induced stop codon read-through</article-title>. <source/>Neurobiol Dis
<year>2012</year>;<volume>48</volume>:<fpage>115</fpage>â<lpage>123</lpage>.<pub-id pub-id-type="pmid">22750526</pub-id></mixed-citation>
</ref>
<ref id="R37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JQ</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Macdonald</surname><given-names>RL</given-names></name></person-group>
<article-title>The GABRG2 mutation, Q351X, associated with generalized epilepsy with febrile seizures plus, has both loss of function and dominant-negative suppression</article-title>. <source/>J Neurosci
<year>2009</year>;<volume>29</volume>:<fpage>2845</fpage>â<lpage>2856</lpage>.<pub-id pub-id-type="pmid">19261880</pub-id></mixed-citation>
</ref>
<ref id="R38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JQ</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Macdonald</surname><given-names>RL</given-names></name></person-group>
<article-title>Trafficking-deficient mutant GABRG2 subunit amount may modify epilepsy phenotype</article-title>. <source/>Ann Neurol
<year>2013</year>;<volume>74</volume>:<fpage>547</fpage>â<lpage>559</lpage>.<pub-id pub-id-type="pmid">23720301</pub-id></mixed-citation>
</ref>
<ref id="R39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JQ</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Macdonald</surname><given-names>RL</given-names></name></person-group>
<article-title>The human epilepsy mutation GABRG2(Q390X) causes chronic subunit accumulation and neurodegeneration</article-title>. <source/>Nat Neuroscience
<year>2015</year>;<volume>18</volume>:<fpage>988</fpage>â<lpage>996</lpage>.<pub-id pub-id-type="pmid">26005849</pub-id></mixed-citation>
</ref>
<ref id="R40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>HO</given-names></name><name><surname>Reid</surname><given-names>CA</given-names></name><name><surname>Single</surname><given-names>FN</given-names></name><name><surname>Davies</surname><given-names>PJ</given-names></name><name><surname>Chiu</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>S</given-names></name></person-group>
<article-title>Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy</article-title>. <source/>Proc Natl Acad Sci U S A
<year>2007</year>;<volume>104</volume>:<fpage>17536</fpage>â<lpage>17541</lpage>.<pub-id pub-id-type="pmid">17947380</pub-id></mixed-citation>
</ref>
<ref id="R41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirose</surname><given-names>S</given-names></name></person-group>
<article-title>A new paradigm of channelopathy in epilepsy syndromes: intracellular trafficking abnormality of channel molecules</article-title>. <source/>Epilepsy Res
<year>2006</year>;<volume>70</volume>(<issue>suppl 1</issue>):<fpage>S206</fpage>â<lpage>S217</lpage>.<pub-id pub-id-type="pmid">16860540</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>